All In Biotech

Drug Trial Radar · NCT07743489

RB-PDT for Fusarium Keratitis: The LUMIERE Study

Light for Ulcer Management by Infection Elimination and Resistance Enhancement (LUMIERE)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 434 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

434

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Apr 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Miami; Aravind Eye Care System; Federal University of São Paulo
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter trial with recruitment planned at ophthalmology clinics specializing in corneal diseases in India, Brazil, and at Stanford University and Bascom Palmer Eye Institute in the United States. Fusarium keratitis is common in tropical and subtropical regions like Florida, India and Brazil, which will facilitate access to the required number of participants. The study aims to recruit a total of 434 participants (217 per group).

Conditions

  • Fusarium Keratitis

Interventions

  • Rose Bengal Photodynamic TherapyDrug

    RB-PDT/sham RB-PDT will occur within 5 days of initial smear/culture. For Group 1, Rose Bengal (0.1% RB in 0.9% sodium chloride) will be applied in 3-minute intervals to the de-epithelialized cornea for 30 minutes followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). A second RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

  • Sham RB-PDTDrug

    Participants in Group 2 will undergo a sham procedure using topical balanced salt solution and pen light covered with a green filter. Study participants will undergo repeat scraping and culture of the corneal ulcer 30 minutes after the assigned RB-PDT procedure. A second sham RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BSCVA at 3 monthsTime frame: 3 months post-op

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • University of Miami - Bascom Palmer Eye Institute

    Miami, Florida

  • Federal University of São Paulo

    São Paulo, Brazil

  • Aravind Eye Care System

    Madurai, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.